Pharmaceutical composition comprising an adenosine A3 receptor agonist (IB-MECA / CF-101) for the treatment of psoriasis

摘要

A pharmaceutical composition for use in the treatment of psoriasis comprising as an active ingredient 1- [N6- (3-iodobenzyl) -adenin-9-yl] -ß-D-ribofuronamide (IB-MECA) in a suitable amount for a daily dose administration of approximately 4 mg.